Barely Significant
← all excerpts

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.

Br J Cancer · 2021 · PMC7853132 · PMID 32994466

Europe PMCDOI
1
hedged sentence
0.0730
closest p · 1.5× alpha
0.0730
boldest claim

The sentences

marginal significanceP = 0.073so close (0.05 < p ≤ 0.1)
On the other hand, belotecan was associated with improved OS with marginal significance in the ITT population (median 31.5 versus 22.9 months, P = 0.073), with the relation becoming stronger in the PP population (median 39.7 versus 26.6 months; P = 0.034).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.